Poster presentation at:
16th December 2005 - 19th December 2005
Washington DC, USA
Larder BA1, Wang D1, Revell AD1, Harrigan R2, Montaner J2, Wegner S3, and Lane C4.
1: HIV Resistance Response Database Initiative, London, UK; 2: BC Centre for Excellence in HIV/AIDS Vancouver, Canada; 3: US Military HIV Research Program, Rockville, MD, USA; 4: National Institute of Allergy & Infectious Diseases, Bethesda, MD, USA.
Background Previous exposure to HAART can result in archived resistant virus, undetectable by conventional genotyping, which may undermine the success of new treatment regimens. We assessed the influence of previous treatment or genotype history on the accuracy of artificial neural networks (ANN) predicting virologic response to HAART.
Methods Study 1: Basic ANN models were trained using 2,559 treatment change episodes (TCEs), i.e. current genotype, baseline viral load (VL), new drugs, follow-up time and VL response. Treatment history models were trained with 4 additional input variables - previous treatment with any of the following: AZT, 3TC, any NNRTI and any PI.
Study 2: Basic models were trained as above and the genotype history models were trained using 301 TCEs containing cumulative data from all available genotypes up to and including baseline.
The ANNs were tested using the input variables of independent test TCEs, which produced a predicted VL response that was compared to the actual response.
Results In all cases, averaged output from 10 ANN models was used. Correlations between predicted and actual VL change for basic and treatment history models gave r@ values of 0.30 and 0.45 respectively (p<0.01). The correlations for the basic and genotypic history models gave r@ values of 0.39 and 0.31 respectively (ns).
Conclusions The addition of treatment history data significantly improved the accuracy of ANN confirming that historical exposure to antiretroviral drugs can influence response to a new regimen. This suggests that treatment history may act as a surrogate for minority mutant populations enabling ANN to overcome this shortcoming of current genotyping. The use of cumulative historical genotype data did not improve the accuracy of the ANN.
New predictive models accurately predict HIV treatment response despite missing data
Predicting HIV therapy response despite missing data - new models published
2021 update to HIV-TRePS: a highly flexible and accurate system for the prediction of treatment response from incomplete baseline information in different healthcare settings
New models that predict treatment outcome without the need for a baseline CD4 count or genotype added to HIV-TRePS
The most accurate models to date for predicting response to HIV therapy are released for clinical use
RDI expands the range of models available through HIV-TRePS to include their most accurate models to date
AI models predict absolute virological response to HIV therapy over time